Supplement Manufacturer & E-Comm in Newark, NJ – $671K EBITDA – Est. 2002
Executive Overview
Key Investment Highlights
- •Established brand since 2002, with current operations founded in 2020
- •Relocatable headquarters, currently based in New Jersey
- •Proprietary manufacturing process supported by extensive scientific research
- •Robust international presence—23% of sales generated from 59 countries
- •Strong historical sales growth, achieving a 48% CAGR
This business leverages a unique, validated manufacturing process and proprietary strains, positioning it as a leader in the metabiotic, postbiotic, and lysate supplement segment. Its products serve a broad spectrum of health needs, including immunomodulatory, antiviral, and probiotic applications. Decades of research underpin the product line, resulting in a loyal global customer base and a strong competitive advantage.
There are substantial opportunities for further growth through strategic investment in marketing, capital, and human resources. The business has demonstrated remarkable sales momentum, increasing from $852,000 in 2021 to $2,770,000 in 2024, while maintaining operational efficiency and minimal capital expenditure—averaging just $11,000 annually in recent years. This positions the business for scalable growth and attractive free cash flow generation.